HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.

AbstractPURPOSE:
Curcumin, a plant-derived natural polyphenol, could be a promising anti-cancer drug and shows synergic effects with cytotoxic agents. We evaluated the safety and feasibility of combination therapy using curcumin with gemcitabine-based chemotherapy.
METHODS:
Gemcitabine-resistant patients with pancreatic cancer received 8 g oral curcumin daily in combination with gemcitabine-based chemotherapy. The primary endpoint was safety for phase I and feasibility of oral curcumin for phase II study.
RESULTS:
Twenty-one patients were enrolled. No dose-limiting toxicities were observed in the phase I study and oral curcumin 8 g/day was selected as the recommended dose for the phase II study. No patients were withdrawn from this study because of the intolerability of curcumin, which met the primary endpoint of the phase II study, and the median compliance rate of oral curcumin was 100% (Range 79-100%). Median survival time after initiation of curcumin was 161 days (95% confidence interval 109-223 days) and 1-year survival rate was 19% (4.4-41.4%). Plasma curcumin levels ranged from 29 to 412 ng/ml in five patients tested.
CONCLUSIONS:
Combination therapy using 8 g oral curcumin daily with gemcitabine-based chemotherapy was safe and feasible in patients with pancreatic cancer and warrants further investigation into its efficacy.
AuthorsMasashi Kanai, Kenichi Yoshimura, Masanori Asada, Atsushi Imaizumi, Chihiro Suzuki, Shigemi Matsumoto, Takafumi Nishimura, Yukiko Mori, Toshihiko Masui, Yoshiya Kawaguchi, Kazuhiro Yanagihara, Shujiro Yazumi, Tsutomu Chiba, Sushovan Guha, Bharat B Aggarwal
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 68 Issue 1 Pg. 157-64 (Jul 2011) ISSN: 1432-0843 [Electronic] Germany
PMID20859741 (Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Drug Combinations
  • Deoxycytidine
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid
  • Curcumin
  • Gemcitabine
Topics
  • Adenocarcinoma (drug therapy, mortality, physiopathology)
  • Aged
  • Antineoplastic Agents (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
  • Curcumin (administration & dosage, adverse effects, pharmacokinetics)
  • Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
  • Drug Combinations
  • Drug Resistance, Neoplasm
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Medication Adherence
  • Middle Aged
  • Oxonic Acid (adverse effects, therapeutic use)
  • Pancreatic Neoplasms (drug therapy, mortality, physiopathology)
  • Survival Rate
  • Tegafur (adverse effects, therapeutic use)
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: